Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.

Liver international : official journal of the International Association for the Study of the Liver - 1 Feb 2012

Manns Michael P, Markova Antoaneta A, Calle Serrano Beatriz, Cornberg Markus

Abstract excerpt

INTRODUCTION: Chronic hepatitis C virus infection affects approximately 2% of the world population and can result in cirrhosis and hepatocellular carcinoma. Until 2011, the standard of care (SOC) has been therapy with pegylated interferon alfa and ribavirin (PEG-IFN/RBV). Sustained virologic response rates (SVR) after SOC in patients infected with genotype 1 have been 40-50%. The development of new direct...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia
Share to Clinical Trials, Phase III as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Delivery Systems

Share to Polyethylene Glycols

Share to Proline

Share to Randomized Controlled Trials as Topic

Share to Ribavirin

Share to Serine Proteinase Inhibitors

Source

Identifiers

PMID: 22212568
DOI: 10.1111/j.1478-3231.2011.02725.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.PMID 22212568Read ↗

Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.Semantic proximity Read ↗

Boceprevir: a protease inhibitor for the treatment of hepatitis C.Semantic proximity Read ↗

Boceprevir in genotype 1 chronic hepatitis C: first experiences in Serbia.Semantic proximity Read ↗

Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.Semantic proximity Read ↗

7 BOCEPREVIR IN ADDITION TO STANDARD OF CARE ENHANCED SVR IN HEPATITIS C VIRUS (HCV) GENOTYPE-1 WITH ADVANCED FIBROSIS/CIRRHOSIS: SUBGROUP ANALYSIS OF SPRINT-2 AND RESPOND-2 STUDIESSemantic proximity Read ↗

Boceprevir for untreated chronic HCV genotype 1 infection.Semantic proximity Read ↗

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.Semantic proximity Read ↗

[Treatment guidelines for patients with genotype 1 chronic hepatitis C infection].Semantic proximity Read ↗

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.Semantic proximity Read ↗

Boceprevir: a recently approved protease inhibitor for hepatitis C virus infection.Semantic proximity Read ↗

Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?Semantic proximity Read ↗

Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.